EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition

Gayatri S Ganesan, Zoë R Moosbrugger, Phoebe S Parker, Noah J Goff iD, Arjun K Kumar, Kara A Bernstein iD

NAR Cancer · 27.07.2026 · 8 (3)

DOI: 10.1093/narcan/zcag018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 20.08.2026. Verfasst von Gayatri S Ganesan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104,United States. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, Poly (ADP-Ribose) Polymerase-1, Breast Neoplasms, DNA-Binding Proteins. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIEHS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The tumor suppressor RAD51C is essential for DNA double-strand break repair through the homologous recombination (HR) pathway. RAD51C loss is linked to an increased risk of breast cancer, but the majority of RAD51C missense mutations identified in patients are variants of unknown significance. In addition to promoting HR, RAD51C also protects damaged replication forks. Here, we characterized 33 clinically identified breast cancer variants and assayed their ability to perform HR. We identified one HR-deficient variant and five variants with intermediate HR proficiency. While these variants have modestly attenuated HR, they misregulate replication fork progression and accumulate single-strand DNA gaps. We then assessed their sensitivity to PARP1 and ATR inhibition. While RAD51C variants with attenuated HR are largely resistant to monotherapy, cells expressing a subset of these RAD51C variants exhibit increased sensitivity to combination PARP1i and ATRi treatment, Saruparib and Ceralasertib, respectively. Collectively, we pinpoint the key functional regions of RAD51C and uncover a new C-terminal region proximal to the ATP-binding site in the folded RAD51C structure. Together, our findings suggest that variants with partial HR function can cause profound defects in the repair of replicative damage, and that this, in turn, may lead to distinct therapeutic responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ataxia Telangiectasia Mutated ProteinsPoly (ADP-Ribose) Polymerase-1Breast NeoplasmsDNA-Binding ProteinsHomologous RecombinationHumansFemalePoly(ADP-ribose) Polymerase InhibitorsPhthalazinesCell Line, Tumor

Substanzen

Ataxia Telangiectasia Mutated ProteinsPoly (ADP-Ribose) Polymerase-1RAD51C protein, humanPARP1 protein, humanDNA-Binding ProteinsATR protein, humanPoly(ADP-ribose) Polymerase InhibitorsPhthalazines

Autor:innen und Institutionen

  • Department of Biochemistry and Biophysics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104,United States.

ORCID-Profile: Noah J Goff, Kara A Bernstein

Förderung

  • NCI NIH HHS
  • NIEHS NIH HHS
  • National Institutes of Health
  • Breast Cancer Coalition
  • American Cancer Society
  • Department of Defense
  • Basser Center for BRCA-related Research

Zitieren

APA

Ganesan, G. S., Moosbrugger, Z. R., Parker, P. S., Goff, N. J., Kumar, A. K., & Bernstein, K. A. (2026). RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition. NAR Cancer, 8(3). https://doi.org/10.1093/narcan/zcag018

Vancouver

Ganesan GS, Moosbrugger ZR, Parker PS, Goff NJ, Kumar AK, Bernstein KA. RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition. NAR Cancer. 2026;8(3). doi:10.1093/narcan/zcag018

BibTeX
@article{Ganesan2026,
  author = {Ganesan, Gayatri S and Moosbrugger, Zoë R and Parker, Phoebe S and Goff, Noah J and Kumar, Arjun K and Bernstein, Kara A},
  title = {RAD51C breast cancer-identified variants with attenuated homologous recombination function exhibit sensitivity to combined PARP1 and ATR inhibition},
  journal = {NAR Cancer},
  year = {2026},
  volume = {8},
  number = {3},
  doi = {10.1093/narcan/zcag018}
}
Kostenlos starten →